| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.003 | 0.9 |
| mRNA | Vorinostat | gCSI | pan-cancer | AAC | 0.0045 | 0.9 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | -0.0027 | 0.9 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | -0.0027 | 0.9 |
| mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | -0.0024 | 0.9 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0039 | 0.9 |
| mRNA | MK-0752 | CTRPv2 | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | paclitaxel | GDSC1000 | pan-cancer | AAC | -0.0039 | 0.9 |
| mRNA | PF-543 | CTRPv2 | pan-cancer | AAC | 0.0027 | 0.9 |